Prostate Cancer

Active Surveillance the Least Costly Management Strategy for Low-Risk Prostate Cancer

Wayne Kuznar

April 2018, Vol 8, No 4 - Prostate Cancer

San Francisco, CA—Active surveillance is less costly than immediate treatment of low-risk prostate cancer, regardless of the specific treatment, according to findings from a cost analysis at a single institution presented at the 2018 Genitourinary Cancers Symposium. The cost-effectiveness of initial active surveillance compared with immediate treatment, as well as mitigation of treatment-related side effects, supports consideration of active surveillance as a management strategy in value-based care models, said lead investigator Franklin Gaylis, MD, FACS, Medical Director, Genesis Healthcare Partners (GHP), San Diego, who presented the study results. [ Read More ]

Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately 2 Years

Phoebe Starr

April 2018, Vol 8, No 4 - GU Cancers Symposium Highlights, Prostate Cancer

In 2 separate studies, apalutamide (Erleada) and enzalutamide (Xtandi) reduced the risk for metastasis and prolonged metastasis-­free survival in patients with nonmetastatic castrate-resistant prostate cancer (CRPC), according to the results of 2 clinical trials presented at the 2018 Genitourinary Cancers Symposium. [ Read More ]

Zytiga Receives New Indication, with Prednisone, for Metastatic, High-Risk Castration-Sensitive Prostate Cancer

March 2018, Vol 8, No 3 - FDA Approvals, News & Updates, Prostate Cancer

On February 7, 2018, abiraterone acetate (Zytiga; Janssen Biotech) received FDA approval for use, in combination with prednisone, for the treatment of patients with metastatic, high-risk castration-sensitive prostate cancer (CSPC). The FDA approved this new indication under its priority review program. [ Read More ]